IN2014DN09594A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09594A
IN2014DN09594A IN9594DEN2014A IN2014DN09594A IN 2014DN09594 A IN2014DN09594 A IN 2014DN09594A IN 9594DEN2014 A IN9594DEN2014 A IN 9594DEN2014A IN 2014DN09594 A IN2014DN09594 A IN 2014DN09594A
Authority
IN
India
Prior art keywords
ophthalmological
vehicle system
eye
cornea
active substance
Prior art date
Application number
Other languages
English (en)
Inventor
Ute Steinfeld
Frank Holzer
Hyeck Hee Lee
Markus Mahler
Original Assignee
F Holzer Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Holzer Gmbh filed Critical F Holzer Gmbh
Publication of IN2014DN09594A publication Critical patent/IN2014DN09594A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
IN9594DEN2014 2012-05-15 2013-05-14 IN2014DN09594A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12168139.9A EP2664329A1 (de) 2012-05-15 2012-05-15 Ophthalmologisches Vehikelsystem
PCT/EP2013/059927 WO2013171204A2 (de) 2012-05-15 2013-05-14 Ophthalmologisches vehikelsystem für arzneistoffe, ophthalmologisches kit sowie verwendung einer ophthalmologischen zusammensetzung

Publications (1)

Publication Number Publication Date
IN2014DN09594A true IN2014DN09594A (enExample) 2015-07-31

Family

ID=48463974

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9594DEN2014 IN2014DN09594A (enExample) 2012-05-15 2013-05-14

Country Status (12)

Country Link
US (1) US20150139973A1 (enExample)
EP (2) EP2664329A1 (enExample)
JP (1) JP2015521182A (enExample)
KR (1) KR20150014966A (enExample)
CN (1) CN104394859A (enExample)
AU (1) AU2013261873A1 (enExample)
CA (1) CA2873265A1 (enExample)
HK (1) HK1202427A1 (enExample)
IN (1) IN2014DN09594A (enExample)
MX (1) MX2014013884A (enExample)
RU (1) RU2014145440A (enExample)
WO (1) WO2013171204A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2666836T3 (es) 2014-06-04 2018-05-08 Alfasigma S.P.A. Formulaciones homogéneas que comprenden ácidos grasos poliinsaturados omega-3 (n-3 PUFA) y resveratrol para administración oral
MX382072B (es) * 2014-06-06 2025-03-12 Archer Daniels Midland Co Microemulsiones y sus usos.
PL3203989T3 (pl) 2014-10-09 2020-06-29 Distretto Tecnologico Sicilia Micro E Nano Sistemi S.C.A.R.L. Nanostrukturalne preparaty do dostarczania sylibininy i innych składników czynnych do leczenia chorób oczu
JP2018510668A (ja) 2015-01-12 2018-04-19 ケダリオン セラピューティックス，インコーポレイテッド 微小液滴の繰り出し装置及び方法
WO2016164830A1 (en) 2015-04-10 2016-10-13 Lagunita Llc Piezoelectric dispenser with replaceable ampoule
KR20180003548A (ko) * 2015-05-12 2018-01-09 라이온 가부시키가이샤 안과용 조성물
EP3128007A1 (en) * 2015-08-07 2017-02-08 Gene Signal International SA Sterile emulsion comprising a stable phosphorothioate oligonucleotide
WO2017025471A1 (en) * 2015-08-07 2017-02-16 Gene Signal International Sa Sterile emulsion comprising a stable phosphorothioate oligonucleotide
ES2846848T3 (es) 2015-10-26 2021-07-29 Harvard College Polisacáridos reducidos y oxidados y métodos de uso de los mismos
WO2018077958A1 (en) 2016-10-27 2018-05-03 Unilever N.V. A personal care composition comprising curcuminoids
JP6134853B1 (ja) * 2016-10-28 2017-05-24 参天製薬株式会社 エピナスチン含有点眼液
CN109906120A (zh) 2017-01-20 2019-06-18 科达莱昂治疗公司 压电流体分配器
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
JP6635974B2 (ja) * 2017-04-24 2020-01-29 参天製薬株式会社 エピナスチン含有点眼液
CN107158020A (zh) * 2017-05-18 2017-09-15 德施普科技发展温州有限公司 一种眼科用药物组合物及其制备方法
CA3083219A1 (en) 2017-12-08 2019-06-13 Reynaldo Quintana Fluid delivery alignment system
KR102094882B1 (ko) * 2017-12-21 2020-04-28 주식회사 유엠아이옵틱스 항균 누점 플러그 및 그 제조방법
US20210145763A1 (en) * 2018-04-04 2021-05-20 Eye Co Pty Ltd Low thc hemp extract and method of treatment or prevention of an eye disease
US12186234B2 (en) 2018-04-12 2025-01-07 Bausch + Lomb Ireland Limited Topical ocular delivery methods and devices for use in the same
US12350194B1 (en) 2018-04-12 2025-07-08 Bausch + Lomb Ireland Limited Topical ocular delivery of fluids with controlled mass dosing and wireless communication
DE102018208110A1 (de) 2018-05-23 2019-11-28 F. Holzer Gmbh Abgabekopf und Abgabevorrichtung zur dosierten Abgabe flüssiger Präparate sowie Verwendungsmöglichkeiten
AU2019297326B2 (en) 2018-07-03 2025-01-09 Bausch + Lomb Ireland Limited Topical ocular delivery devices and methods for using the same
EP3843721A4 (en) * 2018-08-29 2022-10-12 Ocugen, Inc. OPHTHALMIC COMPOSITIONS AND METHODS OF USE
WO2020070751A1 (en) * 2018-10-03 2020-04-09 Tathagata Dutta Semisolid dosage forms for ophthalmic delivery of antioxidants
US11679028B2 (en) 2019-03-06 2023-06-20 Novartis Ag Multi-dose ocular fluid delivery system
US12097145B2 (en) 2019-03-06 2024-09-24 Bausch + Lomb Ireland Limited Vented multi-dose ocular fluid delivery system
DE112020002226T5 (de) * 2019-05-03 2022-01-20 Mark Lobanoff Nahinfrarot-Beleuchtung für chirurgische Verfahren
WO2020250252A1 (en) * 2019-06-11 2020-12-17 Sifi S.P.A. Microemulsion compositions
CN110384584A (zh) * 2019-06-28 2019-10-29 四川省一直牛健康管理有限公司 一款中西方芳香植物配伍的功能性眼罩及其制备方法
WO2021049864A1 (ko) * 2019-09-11 2021-03-18 (주) 메드빌 두릅나무 추출물을 함유하는 안구건조증 개선용 조성물
US12496218B1 (en) 2019-11-12 2025-12-16 Bausch + Lomb Ireland Limited Fractionated topical ocular drug delivery methods and devices for use in the same
JP6736752B2 (ja) * 2019-12-17 2020-08-05 参天製薬株式会社 エピナスチン含有点眼液
CN111269161B (zh) * 2019-12-26 2022-03-08 深圳市真兴生物医药研究中心有限公司 厚朴酚与萝卜硫素拼接物及其制备方法和应用
WO2021183995A1 (en) * 2020-03-13 2021-09-16 Furst-Mcness Company Compositions and methods for prevention and treatment of viral disorders
US12290472B2 (en) 2020-04-17 2025-05-06 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
WO2021212038A1 (en) 2020-04-17 2021-10-21 Kedalion Therapeutics, Inc. Hydrodynamically actuated preservative free dispensing system having a collapsible liquid reservoir
US11938057B2 (en) 2020-04-17 2024-03-26 Bausch + Lomb Ireland Limited Hydrodynamically actuated preservative free dispensing system
CA3180199A1 (en) 2020-04-17 2021-10-21 Yehuda Ivri Hydrodynamically actuated preservative free dispensing system
EP3919047A1 (en) * 2020-06-03 2021-12-08 AZAD Pharma AG Microemulsion for the treatment of dry eye syndrome
US20230226002A1 (en) * 2020-06-15 2023-07-20 University Of Utah Research Foundation Retinal bioavailbility of synthetic very-long-chain polyunsaturated fatty acids
JP2020169213A (ja) * 2020-07-15 2020-10-15 参天製薬株式会社 エピナスチン含有点眼液
WO2022018605A1 (en) * 2020-07-19 2022-01-27 Narayana Nethralaya Foundation A formulation of combination of genistein and calcitriol for management of inflammatory ocular surface conditions
US11033516B1 (en) 2020-09-18 2021-06-15 Spring Discovery, Inc. Combination therapies with disulfiram
EP4218744A4 (en) * 2020-09-25 2024-10-23 Tsubota Laboratory, Inc. PROPHYLACTIC, RELIEF AND THERAPEUTIC AGENT FOR DRY EYE
IT202000026236A1 (it) * 2020-11-04 2022-05-04 Iromed Group S R L Composizione oftalmica
MA66915A1 (fr) * 2022-01-26 2025-10-31 Amarin Pharmaceuticals Ireland Limited Compositions d'acides gras à libération de lymphe et leurs utilisations pour l'incorporation lymphatique et le traitement de maladies systémiques
CN116253891B (zh) * 2022-08-22 2024-09-20 中南大学湘雅医院 Chta-dsb-da高分子载体及其载药纳米材料的制备和在眼科药物中的应用
KR102513994B1 (ko) * 2022-10-26 2023-03-24 김태윤 반려동물의 눈물 착색예방용 조성물
CN116196263A (zh) * 2023-02-23 2023-06-02 河南大学 一种含有干细胞提取物的护肤组合物及其制备方法
CN118477012B (zh) * 2024-05-07 2025-01-21 广州品域美妆创新科技有限公司 一种含胶原的抗皱紧致组合物及其在化妆品中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98747A0 (en) * 1991-07-05 1992-07-15 Yissum Res Dev Co Ophthalmic compositions
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
AU680539B2 (en) * 1993-08-18 1997-07-31 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
US20100173876A1 (en) * 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
AR038628A1 (es) * 2002-03-04 2005-01-19 Novartis Ag Composicion oftalmica
DE60303235T2 (de) 2003-04-09 2006-09-28 Ursapharm Arzneimittel Gmbh & Co. Kg Fluidspender
BRPI0710085B8 (pt) * 2006-03-31 2021-05-25 Vistakon Pharmaceutical Llc composições oftálmicas e seus kits
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
US10201548B2 (en) * 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
ES2564502T3 (es) * 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
DE102010050570A1 (de) * 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors

Also Published As

Publication number Publication date
CN104394859A (zh) 2015-03-04
WO2013171204A3 (de) 2014-01-09
EP2849741A2 (de) 2015-03-25
HK1202427A1 (zh) 2015-10-02
RU2014145440A (ru) 2016-07-10
JP2015521182A (ja) 2015-07-27
AU2013261873A1 (en) 2014-12-04
KR20150014966A (ko) 2015-02-09
CA2873265A1 (en) 2013-11-21
EP2664329A1 (de) 2013-11-20
MX2014013884A (es) 2015-06-23
WO2013171204A2 (de) 2013-11-21
US20150139973A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
IN2014DN09594A (enExample)
MX2020005217A (es) Composicion oftalmica y dispositivo de administracion de la misma.
MY159463A (en) Method and composition for treating ocular hypertension and glaucoma
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
MY171920A (en) Prevention and treatment of ocular conditions
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
BR112014018910A8 (pt) Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
UA115807C2 (uk) Композиція (варіанти) ценікривіроку і спосіб її одержання та застосування (варіанти)
MX2016001023A (es) Formulaciones que contienen dapagliflozina amorfa.
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
EP4414376A3 (en) Novel depsipeptide and uses thereof
GT201300235A (es) Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
HK1198811A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
EA201301332A1 (ru) ОФТАЛЬМОЛОГИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ АНАЛОГ PGF2α
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
IN2014CN02972A (enExample)
PH12012501271A1 (en) Topical ophthalmic peptide formulation
BR112018072127A2 (pt) inibidores de dipeptidil peptidase-4 para o tratamento ocular tópico de doenças neurodegenerativas da retina
EP3587392A8 (en) Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases
BR112015019524A2 (pt) tratamento de combinação